Showing results (351-360 of 432) with videos related to
Sort By:
Pageof 44
The Journal of Clinical Investigation|November 15, 2024
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemiaPaul Deschamps, Margaux Wacheux, Axel Gosseye, et al.Lancet (London, England)|June 13, 2023
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trialUwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, et al.Blood|June 6, 2022
Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysisMarie Robin, Liesbeth C de Wreede, Eric Padron, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2021
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic SyndromesGuillermo Garcia-Manero, Valeria Santini, Antonio Almeida, et al.Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.JCO Clinical Cancer Informatics|June 30, 2023
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in HematologySaverio D'Amico, Daniele Dall'Olio, Claudia Sala, et al.British Journal of Haematology|April 19, 2022
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutationsLionel Adès, Nicolas Duployez, Agnes Guerci-Bresler, et al.Blood|April 20, 2022
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, et al.Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.Leukemia|September 7, 2022
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCOAnne Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth, et al.Pageof 44